{
    "Trade/Device Name(s)": [
        "INNOVANCE Anti-Xa"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K240315",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN190032",
        "K213464",
        "K223187"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLU"
    ],
    "Summary Letter Date": "October 10, 2024",
    "Summary Letter Received Date": "September 10, 2024",
    "Submission Date": "September 10, 2024",
    "Regulation Number(s)": [
        "21 CFR 864.7295"
    ],
    "Regulation Name(s)": [
        "Heparin And Direct Oral Factor Xa Inhibitor Drug Test System"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Unfractionated heparin (UFH)",
        "Low molecular weight heparin (LMWH)",
        "Apixaban"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrated tubes"
    ],
    "Instrument(s)/Platform(s)": [
        "BCS XP System",
        "CS-2500 System",
        "CS-5100 System",
        "CA-660 System"
    ],
    "Method(s)/Technology(ies)": [
        "Automated chromogenic assay",
        "Coagulation analyzer"
    ],
    "Methodologies": [
        "Chromogenic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent",
        "Standard"
    ],
    "Document Summary": "FDA 510(k) summary for INNOVANCE Anti-Xa automated chromogenic assay to measure UFH, LMWH, and apixaban activity in citrated plasma on compatible coagulation analyzers",
    "Indications for Use Summary": "Quantitative determination of UFH, LMWH, and apixaban activity in human plasma from patients undergoing anticoagulant therapy, using specified coagulation analyzers and sodium citrated tubes in the clinical laboratory; not established for neonate or pediatric populations",
    "fda_folder": "Hematology"
}